Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/TA.0b013e318265cf9e http://scihub22266oqcxt.onion/10.1097/TA.0b013e318265cf9e C4516225!4516225!22976421     free     free     free       J+Trauma+Acute+Care+Surg 2012 ; 73 (4): 983-92 Nephropedia Template TP {{tp|p=22976421|t=2012. New anticoagulants: A concise review |pdf=|usr=}}{{22976421}} gab.com Text New anticoagulants: A concise review JO: J Trauma Acute Care Surg http://www.kidney.de/pget.php?&tw=1&pmid=22976421 #FOAvip During the last 2 years, two new oral anticoagulants, dabigatran and rivaroxaban, have been approved in the United States. Phase II and Phase III clinical trials of dabigatran, rivaroxaban, and apixaban are summarized. Approach to perioperative management depends on the half-life of the medication, risk of surgical bleeding, and the patient's renal function. No reversal agent is available for any of the neworal anticoagulants. Management of bleeding patients is based on local measures and consideration of antifibrinolytic therapy and activated factor VII or prothrombin complex concentrate infusion based on healthy volunteer and animal studies. The new oral anticoagulants provide additional options to prevent venous thromboembolism in patients after orthopedic surgery or stroke in patients with atrial fibrillation but present unique challenges compared to warfarin. Twit Text FOAVip New anticoagulants: A concise review ????J Trauma Acute Care Surg http://www.kidney.de/pget.php?&tw=1&pmid=22976421 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=22976421 #FOAvip English Wikipedia <ref>{{Cite pmid|22976421}}</ref> New anticoagulants: A concise review #MMPMID22976421 Kreuziger LMB; Morton CT; Dries DJ J Trauma Acute Care Surg 2012[Oct]; 73 (4): 983-92 PMID22976421show ga During the last 2 years, two new oral anticoagulants, dabigatran and rivaroxaban, have been approved in the United States. Phase II and Phase III clinical trials of dabigatran, rivaroxaban, and apixaban are summarized. Approach to perioperative management depends on the half-life of the medication, risk of surgical bleeding, and the patient's renal function. No reversal agent is available for any of the neworal anticoagulants. Management of bleeding patients is based on local measures and consideration of antifibrinolytic therapy and activated factor VII or prothrombin complex concentrate infusion based on healthy volunteer and animal studies. The new oral anticoagulants provide additional options to prevent venous thromboembolism in patients after orthopedic surgery or stroke in patients with atrial fibrillation but present unique challenges compared to warfarin. äNew anticoagulants: A concise review (epmc).pdf DeepDyve Pubget Overpricing